Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
Novel, AI-Procured ISM001-055 Demonstrates Great Promise for Treatment of IPF
Key ILD Topics at Mount Sinai’s Advances in Pulmonary Medicine 2024
Low Pulmonary Rehabilitation, Palliative Care Referrals for Patients With IPF Persist
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
Learn about the current standard of care for patients with idiopathic pulmonary fibrosis (IPF), including considerations for treatment regimens, disease progression, clinical and economic impact of IPF, and the future of IPF therapies.
Impact of Treatment Delays on Patient Outcomes
Overcoming Treatment Barriers: Strategies for Success
Clinical Presentation and Risk Factors
Impact of Comorbidities on IPF Management
Diagnosing IPF: Key Tests, Time to Diagnosis, and Importance of Early Detection
Impact of IPF on Quality of Life and Financial Considerations
Overview of Idiopathic Pulmonary Fibrosis (IPF)
Unmet Needs in IPF Landscape
Economic Impact of IPF
Key Considerations for Selecting IPF Treatment
Dr Cesar Davila-Chapa Calls for Awareness of Racial Differences in IPF Hospitalization
Role of Immunosuppressive Therapies in Managing ILD
The Impact of FVC Decline and Lung Function in IPF
Promising Clinical Trial Updates in IPF/PPF
Dr Martin Kolb Discusses Combination Therapies and the Future of IPF Treatment
Helping Patients Understand IPF Diagnosis and Treatment
The Role of Lung Transplants in ILD Treatment
Treatment Goals for Patients With ILD
Overcoming Failures: Lessons From IPF Clinical Trials in the Past Year
New Findings Highlight the Impact of Lung Function Decline in IPF, PPF